Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $17.25.

A number of analysts have recently weighed in on the stock. Lifesci Capital raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Robert W. Baird lifted their price objective on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Citigroup upped their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright raised their target price on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $15.76 on Friday. The stock has a market capitalization of $1.73 billion, a P/E ratio of -8.76 and a beta of -0.31. The stock’s fifty day moving average is $13.40 and its 200 day moving average is $11.92. Amylyx Pharmaceuticals has a 52 week low of $2.60 and a 52 week high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. Equities research analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 3,326 shares of Amylyx Pharmaceuticals stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the transaction, the chief financial officer owned 177,104 shares in the company, valued at $1,967,625.44. The trade was a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Camille L. Bedrosian sold 6,580 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $14.35, for a total value of $94,423.00. Following the transaction, the insider directly owned 175,756 shares of the company’s stock, valued at approximately $2,522,098.60. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 157,783 shares of company stock valued at $2,122,808 over the last ninety days. 12.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd acquired a new stake in Amylyx Pharmaceuticals in the third quarter valued at approximately $48,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth $28,000. BNP Paribas Financial Markets increased its holdings in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $45,000. Finally, Legal & General Group Plc bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.